By Dean Seal
South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine.
The Supreme Court of Korea has ruled that the individual conjugates comprising SK Bioscience's 13-valent pneumococcal conjugate vaccine, or PCV13, don't fall within the scope of Pfizer's patent claims, SK Bioscience said Wednesday.
The high court also confirmed that the production and supply of PCV13 finished products for research purposes don't constitute patent infringement, the company said.
A representative for Pfizer didn't immediately respond to a request for comment.
Pfizer claimed in its 2020 suit that SK Bioscience's export of PCV13 individual conjugate bulk substances and research-use finished products to Russia infringed on the composition patent for Prevnar 13, its pneumococcal vaccine.
Now that the ruling has come down, SK Bioscience said it intends to start exporting individual components of PCV13 to countries with high vaccine demand, including nations in Southeast Asia and Latin America.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 21, 2025 08:39 ET (12:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。